- Support a biotech company to commercialize a platform technology to strengthen nucleic acid therapeutics research in Japan
- Maximize value of intellectual properties generated at academia in Japan
- Contribute to facilitate developments of any nucleic acid therapeutics in pipelines at any third parties
Our Portfolio
Rena Therapeutics Inc.
| Outline | R&D of nucleic acid medicine platform technologies based on Hetero-Duplex Oligonucleotide Technology |
|---|---|
| Website | |
| Industry | Health/medicine |
| Commercialization stage | Early stage |
Provided Support
| Authorized Investment | ¥600 million (maximum)／¥300 million* (maximum) |
|---|---|
| Announcement Date | Aug 06, 2015 / Jun 30, 2017 |
| Investment Structure |